Int. J. Mol. Sci. 2009, 10(3), 724-745; doi:10.3390/ijms10030724

Review
Molecular Pathology of Lewy Body Diseases
Katrin Beyer *, Montserrat Domingo-Sàbat and Aurelio Ariza
Department of Pathology, Hospital Universitari Germans Trias i Pujol, Autonomous University of Barcelona, Badalona 08916, Barcelona, Spain; E-Mails: montse.domingo.sabat@gmail.com (M.S.); aurelio.ariza@uab.cat (A.A.)
*
Author to whom correspondence should be addressed; E-Mail: katrinbeyer@hotmail.com; Tel. +34-93-497-88-53; Fax: +34-93-497-88-43
Received: 18 December 2008; in revised form: 3 February 2009 / Accepted: 23 February 2009 /
Published: 26 February 2009

Abstract

: Lewy body diseases are characterized by the presence of Lewy bodies, alpha-synuclein(AS)-positive inclusions in the brain. Since their main component is conformationally modified AS, aggregation of the latter is thought to be a key pathogenic event in these diseases. The analysis of inclusion body constituents gives additional information about pathways also involved in the pathology of synucleinopathies. Widespread mitochondrial dysfunction is very closely related to disease development. The impairment of protein degradation pathways, including both the ubiquitin-proteasome system and the autophagy-lysosome pathway also play an important role during the development of Lewy body diseases. Finally, differential expression changes of isoforms corresponding to genes primarily involved in Lewy body formation point to alternative splicing as another important mechanism in the development of Parkinson’s disease, as well as dementia with Lewy bodies. The present paper attempts to give an overview of recent molecular findings related to the pathogenesis of Lewy body diseases.
Keywords:
Lewy body diseases; Parkinson disease; dementia with Lewy bodies; alpha-synuclein; molecular chaperones; mitochondrial dysfunction; proteosomal dysfunction; alternative splicing; differential isoform expression

Prologue

Lewy body diseases (LBD) share alpha-synuclein (AS) aggregation and Lewy body (LB) formation as their key pathogenic events. The determination of the molecular pathways that lead to AS oligomerization and further aggregation is the basis for the successful design and development of treatments for important neurodegenerative diseases such as Parkinson’s disease (PD) and dementia with Lewy bodies (DLB). After an introduction of the various LBD, this review summarizes molecular findings over the last two years that provide new insight into the pathogenesis of LBD.

1. Lewy body diseases

LBD are characterized by the presence on intraneuronal proteinaceous inclusions called Lewy bodies (LBs) with AS as their main component. Whereas these are found mainly within the brainstem in the case of PD, their widespread distribution through almost all brain areas is a characteristic feature in DLB. Neuropathologically, the presence of LB is accompanied by neurodegeneration in the affected areas, therefore the brainstem affectation in PD causes parkinsonian symptoms and the additional cortical affectation in DLB, dementia.

1.1. Parkinson’s Disease

First described in 1817, PD is the most common progressive movement disorder in the elderly and is characterized by tremor, rigidity, and bradykinesia. There is increasing evidence that PD is a multi-systemic disorder showing both progressive degeneration of the dopaminergic nigrostriatal system and widespread extranigral pathology [13]. In PD, LB pathology first appears in lower brainstem nuclei such as the dorsal motor nucleus of the vagus and the olfactory system (Stages 1–2). Afterwards, ascending progression leads to changes in the coeruleus complex, substantia nigra pars compacta, basal forebrain magnocellular nucleus, subthalamic nucleus, and amygdala (Stages 3–4). Finally, involvement of the neocortex may supervene (Stages 5–6) [1,2].

Over the last few years advances in PD genetics have revealed that mutations are responsible for only a small proportion of cases, the majority being of sporadic origin. Of the six genes responsible for Mendelian forms of PD, the first identified was the AS (SNCA) gene, in which three pathogenic point mutations (A30P, E476K and A53T) as well as duplications and triplications have been detected [37]. Genes involved in PD genetics by mutations in autosomic dominant familial cases the ubiquitin C-terminal hydrolase L1 (UCH-L1) gene [8], the dardarin gene, leucine-rich kinase 2 (LRRK 2) [9] and the HtrA2/Omi gene [10]. DJ-1 gene [11], PTEN-induced putative kinase 1 (PINK1) gene [12] and parkin (PRKN) gene mutations are responsible for autosomal recessive Parkinson cases [13]. Interestingly, the vast majority of PD instances associated with PRKN mutations lack LBs [14]. Sporadic PD has been associated to mutations in the synphilin [8], LRRK 2 [9] and HtrA2/Omi [10] genes and to the S18Y polymorphism of the UCH-L1 gene that lowers the risk to suffer PD [15].

1.2. Dementia with Lewy Bodies

DLB is the second most frequent cause of dementia in the elderly after Alzheimer disease (AD) [16] and is clinically characterized by progressive dementia, often accompanied by parkinsonism and psychiatric symptoms [17]. Widespread distribution of LBs in virtually every brain area is a typical feature of DLB, although the frontal cortex, pigmented midbrain and brainstem nuclei, dorsal efferent nucleus of the vagus, basal forebrain nuclei, and limbic cortical regions are particularly involved [18].

A high percentage of DLB cases show, in addition to LB related pathology, AD characteristic changes [1921], where higher Braak stages of AD-type pathology result in a clinical diagnosis of AD rather than DLB [22]. Accordingly, the misdiagnosis of DLB increases with increasing Braak stages of AD associated pathology [23].

Four mutations, the E46K mutation on SNCA [5], the UCH-L1 gene I93M mutation [8] and two beta-synuclein mutations (V70M and P123H) [24] have been described in four DLB pedigrees. In contrast, up to the present, no genetic marker has been found to be associated with sporadic DLB.

2. Lewy Bodies

Similar to other neurodegenerative disorders, increasing evidence suggests that the presence of compact inclusions may represent a protective mechanism on the part of surviving cells [25,26]. Whereas LBD are characterized by the general neuronal loss of the dopaminergic system, a high percentage of surviving neurons contain intracellular inclusions in the form of LB. These seem to protect the cell by the up-take of misfolded and un-functional proteins [27,28].

2.1. Structure

Morphologically, LBs may be divided into brainstem and cortical types. Whereas brainstem LBs are found in the brainstem nuclei and diencephalon, cortical LBs are preferentially seen in the cerebral limbic cortex and amygdala. Classic brainstem LBs are spherical intraneuronal cytoplasmic inclusions, characterized by hyaline eosinophilic cores, concentric lamellar bands, narrow pale halos, and immunoreactivity for AS and ubiquitin [29]. In contrast, cortical LBs typically lack a halo [30]. AS immunolabeling of PD brains have revealed that AS immunostaining can be detected in approximately 64% of nigral LBs and 31% of cortical LBs [31].

2.2. Components

Up to the present, a large number of proteins has been identified in LBs, but their precise biochemical composition has not yet been elucidated [32].

The main component of inclusion bodies in synucleinopathies is AS and after its initial aggregation, additional proteins are captured and accumulated to the LB. More than 76 LB components have been described so far [33]. They belong to ten different protein classes, including structural elements, AS-binding proteins, synphilin-1-binding proteins, components of the ubiquitin-proteasome system, proteins implicated in cellular responses, proteins associated with phosphorylation and signal transduction, cytoskelatal proteins, cell cycle proteins, cytosolic proteins and others [33].

2.3. Formation

AS aggregation is now accepted as the key step preceding LB formation. Although the precise sequence of events responsible for AS fibrillation remains unknown, advances in elucidating the course of AS aggregation have been attained. First, aggregated AS species with altered solubility as well as substantial accumulation of detergent-soluble and detergent-insoluble AS species of various molecular weights are found particularly in the grey matter [29]. As revealed by ultrastructural studies of AS filaments in LBs, pale bodies, and perikaryal threads, AS perikaryal threads are an early stage of AS filament assembly [34]. Pale bodies occur after incorporation of p62 and assimilation of less aggregated forms of AS [30]. Afterwards, LB appearance would be coincidental with increasing ubiquitin immunoreactivity, due to further incorporation of mono- and di-ubiquitylated AS [35] and capture and [36] accumulation of additional proteins [36,37]. Final stages of LB formation are characterized by involvement of dendrites, LB distortion and finally by LB degradation showing loose filamentous components, decreased AS immunoreactivity, and astroglial process involvement [38].

3. Alpha-synuclein oligomerisation and aggregation – neurotoxicity vs. protection

AS aggregation represents a key event in the pathogenesis of LBD. Therefore, AS structure, conformational behaviour and aggregatory properties have been extensively studied over the last years. Accumulated knowledge can be consulted in many review articles concerning this topic [39,4045].

AS aggregation is preceeded by its oligomerization. But in addition to oligomers that undergo fast transition to a fibrillary state, stable prefibrillar AS oligomers are also detected. These AS protofibrils constitute the deleterious species of the protein [46,47] and are toxic, causing cell death. Specifically, AS 67–82, 72–82 and 72–80 peptides, located within the central or NAC region, display in addition to their toxicity, beta-sheet secondary structure and aggregate forming fibrils [4850]. Three possible mechanisms for AS neurotoxicity have been proposed. First, direct AS interaction with histones inhibiting their acetylation could cause nuclear AS neurotoxicity [51,52], second, AS protofibrils with pore-like activity or with pore-like structure, are able to permeabilize membranes, so disrupting ionic and metabolic homeostasis [45,53] and third, AS was shown to inhibit the function of the neuronal survival factor MEF2D causing about 40% loss of neuronal viability [54].

In contrast, inclusion body formation does not necessarily lead to cell death, but seems to represent a protective mechanism of the cell for survival [25,26]. Nevertheless, it has not been excluded that AS aggregates per se or some event associated with the AS aggregation process are neurotoxic [55]. On one hand, cell and animal models of different neurodegenerative diseases develop inclusion bodies that conversely correlate with cell death [56], and synphilin-1 and synphilin-1A inclusion bodies can be cytoprotective in PD [8,25,57,58]. However, on the other hand, inclusions formed by monoubiquitylated AS increse cell death, and AS inclusions in Drosophila are neurotoxic [59]. Moreover, the fact that monoubiquitylated AS forms amorphous cytotoxic inclusions [35] and that LBs contain amourphous aggregated proteins in the core and fibrils in their periphery [60], imply that LB may be toxic to cells at their initial stages of formation [35]. The further co-aggregation of additional PD-related proteins may counteract this toxicity that is possibly present at initial stages. Nevertheless, to date it is still impossible to predict how LB formation affects dopaminergic neuron viability in PD patients because of their complex protein composition [61].

Ubiquitylation and phosphorylation of both AS and AS aggregation related proteins, are important mechanisms in the regulation of AS aggregation. Whereas about 10% of AS is monoubiquitilated in LBs [62,63], soluble AS is not [63]. Although AS monoubiquitylation rates are low within LBs, these could enhance AS aggregation and seed the formation of inclusion bodies [61].

Parkin, UCH-L1 and PINK1 are also proteins found in LBs [33]. When ubiquitylated, all of them are able to form intracellular inclusions [64,65], indicating that ubiquitylation of different proteins involved in PD may contribute to LB formation [66].

Phosphorylation modulates the ubiquitylation and aggregational properties of various proteins [67]. In addition to being monoubiquitylated, AS is also phosphorylated at serin 129 in LBs [63,68]. Moreover, protein kinases, such as GSK3ß and Cdk5 modulate the death of dopaminergic neurons in pharmakological PD models [69,70]. Of these, Cdk5 phosphorylates parkin at serine 131, decreasing its ability to ubiquitylate synphilin-1 [71]. Parkin moreover decreases synphilin-1 and AS toxicities and promotes inclusion body formation [72].

Synphilin-1, an AS interacting protein, interacts with and is phosphorylated by the protein kinases GSK3ß and casein kinase II (CKII) [73,74]. Whereas GSK3ß decreases synphilin-1 ubiquitylation and inclusion body formation [74], CKII increases inclusion body formation regardless of synphilin-1 ubiquitylation [73,74].

The exhaustive analysis of LB components in dependence on the disease stage may give information about the dysfunction of the various pathways involved in LB disease development.

It is worth mentioning that in addition to AS, all other proteins linked to PD or DLB by disease causing mutations, are also found in LBs. Of these, PINK1, parkin, DJ-1 and HtrA2/Omi are mitochondria related genes, UCH-L1 and also parkin proteasome related proteins, and synphilin-1 has been related to proteosomal dysfunction by its ablity to interact with various proteosomal proteins. Beta-synuclein is an exception, because although mutated in DLB it is not found in LBs, probabely because of its AS-antiaggregatory properties.

4. Mitochondrial dysfunction

Mitochondrial dysfunction, in part thought to be responsible for oxidative stress, is an important factor involved in the preferential cell loss seen for some groups of neurons in the brain [75]. Accordingly, some of the genes that cause recessive parkinsonism are associated, directly or indirectly, with mitochondrial function [7678]. Although recessive parkinsonism differs phenotypically from LBD, in addition to the common feature of prominent nigral cell loss, an important role of mitochondrial dysfunction also in LBD has been suggested. Two of such PD and mitochondrial function related proteins are parkin and PTEN-induced kinase 1 (PINK1) [79,80].

4.1. Parkin

Parkin is an ubiquitin E3 ligase that contains a ubiquitin like domain, two ring finger domains and between the ringfinger domains, a conserved region [81]. As ubiquitin E3 ligase, parkin has been related to the proteasome, but it has not been excluded that this activity can be proteasome independent [80].

Parkin loss-of-function Drosophila models exhibit dramatic defects of mitochondrial morphology [82,83] and parkin knockout mice show signs of oxidative tissue damage in the brain [84]. Although initially several fly and mouse models have located parkin partially in the outer mitochondrial membrane, at steady state it is primarily cystosolic [8486] and it participates in the regulation of mitochondrial function [84,85].

Together with PINK1 parkin constitutes the Pink1/parkin pathway that promotes mitochondrial fission [87,88]. PINK1 could act through a signal transduction cascade promoting parkin dependent ubiquitylation of particular cytoplasmic targets related to mitochondrial morphogenesis [87]. Moreover, parkin is strikingly and specifically recruited to dysfunctional mitochondria, where it regulates their selective removal by autophagy [86,89].

4.2. PINK-1

The PTEN-induced putative kinase, PINK1 localizes predominantly within mitochondria, specifically at the inner mitochondrial membrane [90,91].

PINK-1 loss-of-function Drosophila presents reduced ATP levels as well as mitochondrial DNA content [77,78,92] and mitochondria within dopaminergic neurons present an altered morphology [78]. Since parkin overexpression in flies suppresses all PINK1 mutant phenotypes, but PINK1 overexpression does not compensate for loss of parkin function [77,78,92], PINK1 and parkin seem to act in a linear pathway that affects mitochondrial function with parkin downstream to PINK1 [80]. In peripheral tissues from PD patients with PINK1 [93] and parkin [94] mutations, as well as with sporadic PD [95] have been detected pathological changes and defects in mitochondrial respiration.

Furthermore, PINK1 directly phosphorylates parkin [96] but also the mitochondrial serin protease Omi/HtrA2 [97]. Phosphorylation of parkin induces its translocation to mitochondria so that PINK1 mutations could cause PD by decreased PINK1 kinase activity that at the same time would lead to low parkin levels within mitochondria [96].

4.3. Omi/HtrA2

Omi/HtrA2 contributes to the progression of apoptosis [77,78,98,99]. It is released from the mitochondrial intermembrane space into the cytosol, where it induces apoptotic cell death in addition to the permeabilization of the mitochondrial membrane that at the same time leads to cytochrome c release [98100].

Although Omi/HtrA2 is phosphorylated in a PINK1-dependent manner [97], the functional importance of this interaction remains to be elucidated. However, both PINK1 and Omi/HtrA2 interact and Omi/HtrA2 functions downstream of Pink1 [101]. Surprisingly, there is no evidence of interaction between Omi/HtrA2 and parkin, and both act as independent downstream effectors of PINK1. Although emerging evidence indicates that the PINK1/Parkin pathway is likely to affect mitochondrial dynamics, the function of the PINK1/Omi/HtrA2 pathway is currently unclear [101].

Similar to parkin and PINK1, both the Omi/HtrA2 S399 mutant and the Omi/HtrA2 A141S polymorphism, induce mitochondrial dysfunction associated with altered mitochondrial morphology [102].

5. Dysfunction of protein degradation pathways

The ubiquitin-proteasome system (UPS) and autophagy-lysosome pathway (ALP) are the two most important mechanisms that normally repair or remove abnormal proteins from the cell. Alterations in the function of these systems to degrade misfolded and aggregated proteins are being increasingly recognized to play a fundamental role in the pathogenesis of many neurodegenerative disorders.

If AS degradation depends on the UPS or ALP remains unknown, but both seem to be involved in this process [103]. The recent finding that the inhibition of autophagy leads to the accumulation of monoubiquitilated AS forms followed by its aggregation [61], indicates that autophagy could be the predominant pathway involved in AS clearance [35,61].

5.1. Proteasomal dysfunction

The first indication for UPS dysfunction in diseased neurons was the detection of ubiquitylated proteins in proteinaceous inclusions found in neurodegenerative diseases [104]. Now it is known that polyubiquitylation is the canonical signal for targeting proteins to the proteasome for degradation [67]. Monoubiquitilation, on the contrary, regulates different cellular functions such as protein sorting in the late endosomal pathway, histone function and DNA repair [105].

The involvement of the UPS dysfunction in PD was further underlined by the finding of decreased proteasome activity in sustancia nigra of PD brains [106]. Parkin, not only involved in mitochondrial function and dysfunction, is together with UCH-L1, a component of the UPS. Some familial PD forms are caused by mutations in their genes [107], and whereas parkin polyubiquitilates a rare glycosylated AS form [108], UCH-L1 polyubiquilates AS in vitro [109].

5.1.1. UCH-L1

Linked to the UPS, the ubiquitin C-terminal hydrolase UCH-L1 is an abundant neuronal protein that moreover stabilizes free ubiquitin [110]. A missense mutation, I93M, has been detected in a German family with PD [107], and the S18Y polymorphism was found to be protective against PD in different populations [111,112]. Whereas the I93M mutant decreases UCH-L1 hydrolase activity by 50% [107], the protective S18Y variant results in a slight increase of hydrolase activity [113].

Moreover, it has been recently shown that the UCH-L1 S18Y variant acts as a potent antioxidant [110], protecting cells from induced oxidative damage in different cell models [110]. Its overexpression leads to protein aggregation, but not to apoptosis [110].

5.1.2. SIAH-1

SIAH-1, along with parkin and UCH-L1, belongs to the UPS and is also an E3 ubiquitin ligase that has been detected in LB of PD patients [57]. SIAH-1 regulates the ubiquitilation and degradation of synaptophysin [114] and its interaction with synphilin-1 [57,58,71] is followed by synphilin-1 polyubiquitylation and proteosomal degradation [115].

Furthemore, SIAH-1 seems to play a critical role in the regulation of AS aggregation and toxicity [66]. In contrast to polyubiquitylation of synaptophysin and synphilin-1, SIAH-1 interacts with and mono- and di-ubiquitylates AS [55,61]. AS purified from LB is ubiquitylated at lysines 12, 21, and 23 [63].

5.1.3. Synphilin-1

Synphilin-1 was originally identified as an AS interacting protein [116] and its co-expression with AS in cell cultures leads to the formation of LB-like inclusions [73,116,117].

Even if synphilin-1 is not located within the UPS, it is able to interact with various UPS related proteins. As a 919 amino acid protein, synphilin-1 contains different domains such as ankyrin-like repeats, a coiled-coil domain and a putative ATP,GTP-binding domain [116]. Moreover, synphilin-1 localizes in the presynapse where it binds to synaptic vesicles [117] and may affect dopamine release [115].

The first evidence that synphilin-1 interferes with the proteosomal function was that synphilin-1 overexpression decreases of the reporter protein (GFPu) degradation, a protein normally highly degraded by the proteasome [74]. In addition, synphilin-1 interacts with two proteasome subunits/regulators, S6 ATPase (tbp7) and NUB1 [66]. Its interaction with S6 decreases proteasome function on one hand and co-expression of synphilin-1 and the S6 subunit increases the formation of aggresome-like intracytoplasmic inclusions, on the other [118]. Both not only co-localize in these inclusions, but also in LBs in PD [118].

Finally, synphilin-1 interacts with three E3 ubiquitin ligases: parkin, SIAH, dorfin. Whereas both parkin and SIAH ubiquitylate synphilin-1, followed by inclusions body formation, non-ubiquitylated synphilin-1 is not able to form inclusions [57,74,117,119].

Because of its main characteristic to interact with multiple proteins and many of these are directly related to LB diseases, it has been proposed that synphilin-1 may assemble these proteins into a multi-protein complex [66]. Accordingly it is located within the core of brainstem LB, but is also detected in cortical LB [33].

5.2. Dysfunction of the autophagy-lysosomal pathway

ALP comprises three distinct pathways based on the ways substrates reach the lysosomal lumen: macroautophagy, or autophagy, microautophagy and chaperone-mediated autophagy (CMA) [120]. Of these, CMA selectively degrades cytosolic proteins [121]. In contrast to the UPS, autophagy seems to be the primary mechanism involved in the degradation of long-lived, stable proteins. Moreover, it is the only mechanism by which entire organelles such as mitochondria and large membrane proteins and protein complexes are recycled [120,122].

Evidence for the involvement of lysosomal dysfunction in LBD has been obtained during the last years. Deficiency of the lysosomal enzyme cathepsin D leads to the accumulation of endogenous AS in neurons without the overabundance of its mRNA. Conversely, cathepsin D overexpression reduces AS aggregation and shows a neuroprotective effect against AS overexpression-induced cell death in vitro [123]. Moreover, wild-type AS, but not mutant AS, is selectively translocated into lysosomes for degradation by the CMA pathway [120]. Mutant AS show a very increased affinity to lysosomal membrane receptors, a fact that could explain the failure of CMA to clear it [120].

Finally, very recently, lysosomal dysfunction has been directly related to AS overexpression and accumulation. A study on the regulation of the myocyte enhancer factor 2D (MEF2D), a neuronal survival factor, revealed that AS disrupts MEF2D CMA-mediated degradation [54]. MEF2D, normally located within the neuronal nucleus [121], translocates to the cytoplasm where it is degraded by the lysosomal system [54]. Overexpression of both wild type and mutated AS, inhibits the uptake of MEF2D by lysosomes and its degradation.

6. Alternative splicing

Alternative splicing is a versatile and widespread mechanism for the generation of multiple mRNAs from a single transcript. It leads to significant changes in protein secondary structure and these modifications may cause functional alterations by the specific deletion of functional protein domains. In the last few years an increasing number of genes involved in neurodegenerative disorders have been shown to express more than one splice variant differentially.

Examples include the presenilin (PS) genes (PS1 and PS2), both of which undergo alternative splicing. Of the PS1 isoforms, one lacks exon 9 and the other two variably incorporate four amino acids (VRSQ) on exon 4 [124]. The four amino acid VRSQ-lacking isoform binds to the RabGDP dissociation inhibitor (rabGDI), whereas the VRSQ-containing isoform does not, a finding that constitutes the first evidence of a specific function for the different isoforms [125]. On the other hand, one of PS2 transcript variants lacks exon 5, resulting in a short, truncated protein which is differentially overexpressed in AD [126].

Another alternatively spliced gene is tau, of which six isoforms resulting from complex splicing events are expressed in the adult brain [127129]. The inclusion of exon 10, which codes for an additional microtubule-binding domain, causes frontotemporal dementia with parkinsonism [130]. Finally, it has been recently shown that differential expression of parkin and synphilin transcript variants is altered in LBDs [57,131].

6.1. AS alternative splicing

Thus, four AS isoforms that result from alternative splicing have been described [39,132]. In addition to AS 140, representing the whole and major transcript of the protein [132134], three other isoforms also exist: AS 126, AS 112 and AS 98. Whereas inframe deletions of exons 3 or 5 give rise to AS 126 and AS 112, respectively [133,134], the deletion of both exons 3 and 5 is found in AS 98 [132]. Exon 3 encodes for residues 41–54 within the N-terminus and its deletion results in the interruption of the four amphipathic α-helices of the membrane-binding domain. In contrast, exon 5 encodes for residues 103–130 within the C-terminus, and its splice out shortens the unstructured AS part. Finally, AS 98 mainly preserves the central region of the protein intact. These structural changes resulting from alternative splicing of AS RNA strongly indicate functional changes of the shortened protein isoforms [132,135,136].

6.1.1. AS 126

AS 126 could represent an AS isoform with diminished aggregation properties due to the interruption of the membrane binding domain thought to be necessary during the first steps of AS aggregation [137]. In this context, we have shown that a polymorphic polyT site located in intron 2, co-regulates AS 126 expression levels in the brain and that high-AS 126-expression genotypes accumulate with aging in normal controls [138]. Additionally, AS 126 mRNA levels are drastically decreased in LBD frontal cortices in comparison with controls [135]. Both findings suggest that AS126 plays a protective role in the aging brain.

6.1.2. AS112

On the contrary, AS 112, that shows the shortening of the unorganized AS C-terminal, could be characterized by increased aggregation properties. Accordingly, isoform expression profiles obtained in frontal cortices of LB diseases revealed AS 112 overexpression, specifically in DLB [139].

Interestingly, initial perikaryal AS accumulation seems to be specifically constituted by AS112 [39,139]. AS112 lacks part of the unfolded protein C-terminal but conserves intact membrane-protein and protein-protein binding domains. Therefore, AS112 appears to be an aggregation-prone isoform with enhanced membrane-binding properties [39,139]. Additionally, the fact that aggregation of AS is preceded by its interaction with membranes [137] and that the small fraction of membrane-bound AS seeds the accumulation of the far more abundant cytosolic form [140], point to the AS112 membrane-protein interaction domain as a crucial element in early aggregation steps [39].

6.1.3. AS98

Finally, since AS 98 preserves mainly an unchanged central region that contains aggregation-prone (amino acids 71–82) and toxic (amino acids 67–82, 72–82) sequences [4850,141], it could be the most amyloidogenic and toxic AS isoform. Accordingly, AS 98 mRNA is overexpressed in LBD as well as Alzheimer disease [132].

6.2. Synphilin-1 alternative splicing

In addition to the differential expression of AS isoforms, alternative splicing of other genes with an important involvement in LBD pathogenesis seems also to be affected. Of these, synphilin-1 bears 8 isoforms as result of alternative splicing.

As a major AS interaction protein on one hand [116] and as a parkin substrate on the other [117,119,142], the main functional synphilin-1 domains are responsible for the interaction with them. They are variably shortened in the transcript variants synphilin-1A, 1B and 1C. The four shortest isoforms correspond to truncated, probably unfuntional proteins.

6.2.1. Synphilin-1A

Synphilin-1A is an unusual splice variant of synphilin-1 [58]. It is characterized by a different start codon leading at the same time to a different initial reading frame. Moreover, synphilin-1A lacks the first 394 amino acids and contains additional, very protein specific, amino acid streches, one at the N-and the other on the C-terminus [58].

Synphilin-1A is an aggregation-prone and neurotoxic protein but forms nevertheless neuroprotective inclusions. Moreover, that synphilin-1A interacts with synphilin-1 as well as AS and localizes in LBs, suggesting that synphilin-1A performs its own, isoform-specific function [117,143]. In this context, synphilin-1A’s early involvement during LBD pathogenesis could be confirmed by our finding of synphilin-1A overexpression in PD together with its normal levels in pDLB [136].

Due to its intrinsic neurotoxicity, interaction changes between synphilin-1A and AS could be involved not only in in LB formation but also in dopaminergic neuronal death [66].

6.3. Parkin alternative splicing

So far, 7 different transcript variants (TV) of parkin have been identified. Parkin as one of E3-ubiquitin ligases [124], contains an ubiquitin-like as well as a ring-finger domain, both involved in ubiquitylation of a specific substrate. Parkin isoforms TV2 and TV3 show a shortened sequence between functional domains [144], possibly leading to changes in the efficiency of substrate recognition or ubiquitylation.

As a possible result, the shortened isoforms of synphilin-1 and parkin could present stronger interactions than normal-length proteins. The non-dissociation of synphilin-1 – parkin or synphilin-1 – AS complexes could play an important role during the protein aggregation that precedes LB formation. SNCA and synphilin-1 overexpression in PD frontal cortex, a region not yet affected by LB pathology, underlines this idea, and is further supported by the finding that synphilin-1 and parkin are early components of LBs [119,143].

6.4. Isoform expression profiles

Recently, we have obtaind isoform exression profiles composed by the 4 AS, 4 synphilin-1 and 7 parkin isoforms [136]. We have shown that the different LB diseases present their own isoform expression profiles in frontal cortex. Changes in protein-protein interactions resulting from the lack or overrepresentation of some of the isoforms could be responsible for diminution or gain of function. Since both parkin and synphilin-1 are involved in the proteasome mediated protein degradation, and an important proteasome dysfunction can be observed in synucleinopathies, one of the mechanisms leading to such a dysfunction could be the alteration of alternative splicing.

Moreover, the results strongly support the idea that the different LBD are characterized by their own molecular mechanisms of disease development. Furthermore, our data strengthen the hypothesis that different molecular mechanisms lead to the development of similar neuropathological changes. Elucidating these different mechanisms, as well as ascertaining the clinical diagnosis of LB diseases, will help in the development of appropriate and efficient treatments for each of them.

Conclusions

A main characteristic of LBD, similar to other neurodegenerative conditions, is their genetic heterogeneity. Whereas multiple forms of familial PD are caused by mutations in at least seven different genes, sporadic cases that represent the majority of all LBD do not show a defined genetic profile. This observation, in addition to the alteration of multiple pathways during disease development, suggests the existence of more than one subtype of each disease where similar neuropathological changes are the result of different primary molecular mechanisms.

All patients with clinical diagnosis of PD or DLB, present LBs when analyzed in a post-mortem, neuropathologic study. The only exception are juvenile PD cases caused by mutations in the parkin gene. In contrast, LBs are also found in a relative high percentage of asymptomatic individuals [145,146]. These observations strongly indicate that some individuals are provided by protective mechanisms against LBD, but that LBs and their formation process are closely related to disease development. Although the sequence of brain area affectation is now well-known, neither the earliest mechanisms responsible for AS aggregation nor their chronological order have been determined. Indeed, the exact sequence of pathological alterations that finally lead to disease development remains unknown. Taken together these observations, it would seem that efficient treatments will differ in all PD and DLB groups, or even in patients.

This work was supported by Spain’s Ministry of Health FIS grant PI 050867, Catalonia’s AGAUR grant 2005SGR828, and MaratóTV3 grant 06/1410. We thank Mr. Gary Shivel for his editorial assistance.

References

  1. Braak, H; Del Tredici, K; Bratzke, H; Hamm-Clement, J; Sandmann-Keil, D; Rüb, U. Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson’s disease (preclinical and clinical stages). J Neurol 2002, 249(III), 1–5.
  2. Braak, H; Rub, U; Gai, WP; Del Tredici, K. Idiopathic Parkinson’s disease: Possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J. Neural. Transm 2003, 110, 517–536.
  3. Kruger, R; Kuhn, W; Muller, T; Woitalla, D; Graeber, M; Kösel, S; Przuntek, H; Epplen, JT; Schöls, L; Riess, O. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson’s disease. Nat. Genet 1998, 18, 106–108.
  4. Polymeropoulos, MH; Lavedan, C; Leroy, E; Ide, SE; Dehejia, A; Dutra, A; Pike, B; Root, H; Rubenstein, J; Boyer, R; et al. Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science 1997, 276, 2045–2047.
  5. Zarranz, JJ; Alegre, J; Gomez-Esteban, JC; Lezcano, E; Ros, R; Ampuero, I; Vidal, L; Hoenicka, J; Rodriguez, O; Atarés, B; et al. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol 2004, 55, 164–173.
  6. Singleton, AB; Farrer, M; Johnson, J; Singleton, A; Hague, S; Kachergus, J; Hulihan, M; Peuralinna, T; Dutra, A; Nussbaum, R; et al. Alpha-synuclein locus triplication causes Parkinson’s disease. Science 2003, 302, 841.
  7. Nishioka, K; Hayashi, S; Farrer, MJ; Singleton, AB; Yoshino, H; Imai, H; Kitami, T; Sato, K; Kuroda, R; Tomiyama, H; et al. Clinical heterogeneity of alpha-synuclein gene duplication in Parkinson’s disease. Ann. Neurol 2006, 59, 298–309.
  8. Marx, FP; Holzmann, C; Strauss, KM; Eberhardt, O; Gerhardt, E; Cookson, MR; Hernandez, D; Farrer, MJ; Kachergus, J; Engelender, S; et al. Identification and functional characterization of a novel R621C mutation in the synphilin-1 gene in Parkinson’s disease. Hum. Mol. Genet 2003, 12, 1223–1231.
  9. Hernandez, D; Paisan Ruiz, C; Crawley, A; Malkani, R; Werner, J; Gwinn-Hardy, K; Dickson, D; Wavrant Devrieze, F; Hardy, J; Singleton, A. The dardarin G 2019 S mutation is a common cause of Parkinson’s disease but not other neurodegenerative diseases. Neurosci. Lett 2005, 389, 137–139.
  10. Strauss, KM; Martins, LM; Plun-Favreau, H; Marx, FP; Kautzmann, S; Berg, D; Gasser, T; Wszolek, Z; Müller, T; Bornemann, A; et al. Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson’s disease. Hum. Mol. Genet 2005, 14, 2099–2111.
  11. Maraganore, DM; Wilkes, K; Lesnick, TG; Strain, KJ; de Andrade, M; Rocca, WA; Bower, JH; Ahlskog, JE; Lincoln, S; Farrer, MJ. A limited role for DJ1 in Parkinson disease susceptibility. Neurology 2004, 63, 550–553.
  12. Gosal, D; Ross, OA; Toft, M. Parkinson’s disease: The genetics of a heterogeneous disorder. Eur. J. Neurol 2006, 13, 616–627.
  13. Hedrich, K; Eskelson, C; Wilmot, B; Marder, K; Harris, J; Garrels, J; Meija-Santana, H; Vieregge, P; Jacobs, H; Bressman, SB; et al. Distribution, type, and origin of Parkin mutations: Review and case studies. Mov. Disord 2004, 19, 1146–1157.
  14. Hattori, N; Mizuno, Y. Pathogenetic mechanisms of parkin in Parkinson’s disease. Lancet 2004, 364, 722–724.
  15. Nishikawa, K; Li, H; Kawamura, R; Wang, YL; Hara, Y; Hirokawa, T; Manago, Y; Amano, T; Noda, M; Aoki, S; Wada, K. Alterations of structure and hydrolase activity of parkinsonism-associated human ubiquitin carboxyl-terminal hydrolase L1 variants. Biochem. Biophys. Res. Commun 2003, 304, 176–183.
  16. Jellinger, KA. Neuropathological spectrum of synucleinopathies. Mov. Disord 2003, 18, S2–12.
  17. McKeith, IG; Galasko, D; Kosaka, K; Perry, EK; Dickson, DW; Hansen, LA; Salmon, DP; Lowe, J; Mirra, SS; Byrne, EJ; et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996, 47, 1113–1124.
  18. Neef, D; Walling, AD. Dementia with Lewy bodies: An emerging disease. Am. Fam. Physician 2006, 73, 1223–1229.
  19. Lopez, OL; Becker, JT; Kaufer, DI; Hamilton, RL; Sweet, RA; Klunk, W; DeKosky, ST. Research evaluation and prospective diagnosis of dementia with Lewy bodies. Arch. Neurol 2002, 59, 43–46.
  20. Del Ser, T; Hachinski, V; Merskey, H; Munoz, DG. Clinical and pathologic features of two groups of patients with dementia with Lewy bodies: Effect of coexisting Alzheimer-type lesion load. Alzheimer Dis. Assoc. Disord 2001, 15, 31–44.
  21. Merdes, AR; Hansen, LA; Jeste, DV; Galasko, D; Hofstetter, CR; Ho, GJ; Thal, LJ; Corey-Bloom, J. Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies. Neurology 2003, 60, 1586–1590.
  22. McKeith, IG; Dickson, DW; Lowe, J; Emre, M; O’Brien, JT; Feldman, H; Cummings, J; Duda, JE; Lippa, C; Perry, EK; et al. Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium. Neurology 2005, 65, 1863–1872.
  23. Weisman, D; Cho, M; Taylor, C; Adame, A; Thal, LJ; Hansen, LA. In dementia with Lewy bodies, Braak stage determines phenotype, not Lewy body distribution. Neurology 2007, 69, 356–359.
  24. Ohtake, H; Limprasert, P; Fan, Y; Onodera, O; Kakita, A; Takahashi, H; Bonner, LT; Tsuang, DW; Murray, IV; Lee, VM; et al. Beta-synuclein gene alterations in dementia with Lewy bodies. Neurology 2004, 63, 805–811.
  25. Tanaka, M; Kim, YM; Lee, G; Junn, E; Iwatsubo, T; Mouradian, MM. Aggresomes formed by alpha-synuclein and synphilin-1 are cytoprotective. J. Biol. Chem 2004, 279, 4625–4631.
  26. Tompkins, MM; Hill, WD. Contribution of somal Lewy bodies to neuronal death. Brain Res 1997, 775, 24–29.
  27. Olanow, CW; Perl, DP; DeMartino, GN; McNaught, KS. Lewy-body formation is an aggresome-related process: A hypothesis. Lancet Neurol 2004, 3, 496–503.
  28. Shults, CW. Lewy bodies. Proc. Natl. Acad. Sci. USA 2006, 103, 1661–1668.
  29. Campbell, BC; McLean, CA; Culvenor, JG; Gai, WP; Blumbergs, PC; Jäkälä, P; Beyreuther, K; Masters, CL; Li, QX. The solubility of alpha-synuclein in multiple system atrophy differs from that of dementia with Lewy bodies and Parkinson’s disease. J. Neurochem 2001, 76, 87–96.
  30. Gomez-Tortosa, E; Newell, K; Irizarry, MC; Sanders, JL; Hyman, BT. Alpha-synuclein immunoreactivity in dementia with Lewy bodies: Morphological staging and comparison with ubiquitin immunostaining. Acta Neuropathol 2000, 99, 352–357.
  31. Sakamoto, M; Uchihara, T; Hayashi, M; Nakamura, A; Kikuchi, E; Mizutani, T; Mizusawa, H; Hirai, S. Heterogeneity of nigral and cortical Lewy bodies differentiated by amplified triple-labeling for alpha-synuclein, ubiquitin, and thiazin red. Exp. Neurol 2002, 177, 88–94.
  32. Beyer, K; Ariza, A. Protein aggregation mechanisms in synucleinopathies: Commonalities and differences. J. Neuropathol. Exp. Neurol 2007, 66, 965–974.
  33. Wakabayashi, K; Tanji, K; Mori, F; Takahashi, H. The Lewy body in Parkinson’s disease: Molecules implicated in the formation and degradation of alpha-synuclein aggregates. Neuropathology 2007, 27, 494–506.
  34. Arima, K; Ueda, K; Sunohara, N; Hirai, S; Izumiyama, Y; Tonozuka-Uehara, H; Kawai, M. Immunoelectron-microscopic demonstration of NACP/alpha-synuclein-epitopes on the filamentous component of Lewy bodies in Parkinson’s disease and in dementia with Lewy bodies. Brain Res 1998, 808, 93–100.
  35. Engelender, S. Ubiquitination of alpha-synuclein and autophagy in Parkinson’s disease. Autophagy 2008, 4, 372–374.
  36. Orosz, F; Kovács, GG; Lehotzky, A; Oláh, J; Vincze, O; Ovádi, J. TPPP/p25: from unfolded protein to misfolding disease: Prediction and experiments. Biol. Cell 2004, 96, 701–711.
  37. Kuusisto, E; Parkkinen, L; Alafuzoff, I. Morphogenesis of Lewy bodies: Dissimilar incorporation of alpha-synuclein, ubiquitin, and p62. J. Neuropathol. Exp. Neurol 2003, 62, 1241–1253.
  38. Katsuse, O; Iseki, E; Marui, W; Kosaka, K. Developmental stages of cortical Lewy bodies and their relation to axonal transport blockage in brains of patients with dementia with Lewy bodies. J. Neurol. Sci 2003, 211, 29–35.
  39. Beyer, K. Alpha-synuclein structure, posttranslational modification and alternative splicing as aggregation enhancers. Acta Neuropathol 2006, 112, 237–251.
  40. Uversky, VN. Alpha-synuclein misfolding and neurodegenerative diseases. Curr. Protein Pept. Sci 2008, 9, 507–540.
  41. Irvine, GB; El-Agnaf, OM; Shankar, GM; Walsh, DM. Protein aggregation in the brain: The molecular basis for Alzheimer’s and Parkinson’s diseases. Mol. Med 2008, 14, 451–464.
  42. Uversky, VN. Neuropathology, biochemistry, and biophysics of alpha-synuclein aggregation. J. Neurochem 2007, 103, 17–37.
  43. Clayton, DF; George, JM. The synucleins: A family of proteins involved in synaptic function, plasticity, neurodegeneration and disease. Trends Neurosci 1998, 21, 249–254.
  44. Uversky, VN. A protein-chameleon: conformational plasticity of alpha-synuclein, a disordered protein involved in neurodegenerative disorders. J. Biomol. Struct. Dyn 2003, 21, 211–234.
  45. Volles, MJ; Lansbury, PT, Jr. Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson’s disease. Biochemistry 2003, 42, 7871–7878.
  46. Caughey, B; Lansbury, PT. Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu. Rev. Neurosci 2003, 26, 267–298.
  47. Lashuel, HA; Grillo-Bosch, D. In vitro preparation of prefibrillar intermediates of amyloid-beta and alpha-synuclein. Methods Mol. Biol 2005, 299, 19–33.
  48. Bodles, AM; Guthrie, DJ; Greer, B; Irvine, GBJ. Identification of the region of non-Abeta component (NAC) of Alzheimer’s disease amyloid responsible for its aggregation and toxicity. Neurochemistry 2001, 78, 384–395.
  49. Bodles, AM; Guthrie, DJ; Harriott, P; Campbell, P; Irvine, GB. Toxicity of non-abeta component of Alzheimer’s disease amyloid, and N-terminal fragments thereof, correlates to formation of beta-sheet structure and fibrils. Eur. J. Biochem 2000, 267, 2186–2194.
  50. El-Agnaf, OM; Irving, GB. Aggregation and neurotoxicity of alpha-synuclein and related peptides. Biochem. Soc. Trans 2002, 30, 559–565.
  51. Goers, J; Manning-Bog, AB; McCormack, AL; Millett, IS; Doniach, S; Di Monte, DA; Uversky, VN; Fink, AL. Nuclear localization of alpha-synuclein and its interaction with histones. Biochemistry 2003, 42, 8465–8471.
  52. Kontopoulos, E; Parvin, JD; Feany, MB. Alpha-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity. Hum. Mol. Genet 2006, 15, 3012–3023.
  53. Lashuel, HA; Petre, BM; Wall, J; Simon, M; Nowak, RJ; Walz, T; Lansbury, PT, Jr. Alpha-synuclein, especially the Parkinson’s disease-associated mutants, forms pore-like annular and tubular protofibrils. J. Mol. Biol 2002, 322, 1089–1102.
  54. Yang, Q; She, H; Gearing, M; Colla, E; Lee, M; Shacka, JJ; Mao, Z. Regulation of survival factor MEF2D by chaperone-mediated autophagy. Science 2009, 323, 124–127.
  55. Lee, JT; Wheeler, TC; Li, L; Chin, LS. Ubiquitination of alpha-synuclein by Siah-1 promotes alpha-synuclein aggregation and apoptotic cell death. Hum. Mol. Genet 2008, 17, 906–917.
  56. Ross, CA; Poirier, MA. Opinion: What is the role of protein aggregation in neurodegeneration? Nat. Rev. Mol. Cell. Biol 2005, 6, 891–898.
  57. Liani, E; Eyal, A; Avraham, E; Shemer, R; Szargel, R; Berg, D; Bornemann, A; Riess, O; Ross, CA; Rott, R; Engelender, S. Ubiquitylation of synphilin-1 and alpha-synuclein by SIAH and its presence in cellular inclusions and Lewy bodies imply a role in Parkinson’s disease. Proc. Natl. Acad. Sci. USA 2004, 101, 5500–5505.
  58. Eyal, A; Szargel, R; Avraham, E; Liani, E; Haskin, J; Rott, R; Engelender, S. Synphilin-1A: An aggregation-prone isoform of synphilin-1 that causes neuronal death and is present in aggregates from alpha-synucleinopathy patients. Proc. Natl. Acad. Sci. USA 2006, 103, 5917–5922.
  59. Periquet, M; Fulga, T; Myllykangas, L; Schlossmacher, MG; Feany, MB. Aggregated alpha-synuclein mediates dopaminergic neurotoxicity in vivo. J. Neurosci 2007, 27, 3338–3346.
  60. Baba, M; Nakajo, S; Tu, PH; Tomita, T; Nakaya, K; Lee, VM; Trojanowski, JQ; Iwatsubo, T. Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson’s disease and dementia with Lewy bodies. Am. J. Pathol 1998, 152, 879–884.
  61. Rott, R; Szargel, R; Haskin, J; Shani, V; Shainskaya, A; Manov, I; Liani, E; Avraham, E; Engelender, S. Monoubiquitylation of alpha-synuclein by seven in absentia homolog (SIAH) promotes its aggregation in dopaminergic cells. J. Biol. Chem 2008, 283, 3316–3328.
  62. Tofaris, GK; Razzaq, A; Ghetti, B; Lilley, KS; Spillantini, MG. Ubiquitination of alpha-synuclein in Lewy bodies is a pathological event not associated with impairment of proteasome function. J. Biol. Chem 2003, 278, 44405–44411.
  63. Anderson, JP; Walker, DE; Goldstein, JM; de Laat, R; Banducci, K; Caccavello, RJ; Barbour, R; Huang, J; Kling, K; Lee, M; et al. Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J. Biol. Chem 2006, 281, 29739–29752.
  64. Junn, E; Lee, SS; Suhr, UT; Mouradian, MM. Parkin accumulation in aggresomes due to proteasome impairment. J. Biol. Chem 2002, 277, 47870–47877.
  65. Muqit, MM; Abou-Sleiman, PM; Saurin, AT; Harvey, K; Gandhi, S; Deas, E; Eaton, S; Payne Smith, MD; Venner, K; Matilla, A. Altered cleavage and localization of PINK1 to aggresomes in the presence of proteasomal stress. J. Neurochem 2006, 98, 156–169.
  66. Szargel, R; Rott, R; Engelender, S. Synphilin-1 isoforms in Parkinson’s disease: Regulation by phosphorylation and ubiquitylation. Cell Mol. Life Sci 2008, 65, 80–88.
  67. Hershko, A; Ciechanover, A. The ubiquitin system. Annu. Rev. Biochem 1998, 67, 425–479.
  68. Hasegawa, M; Fujiwara, H; Nonaka, T; Wakabayashi, K; Takahashi, H; Lee, VM; Trojanowski, JQ; Mann, D; Iwatsubo, T. Phosphorylated alpha-synuclein is ubiquitinated in alpha-synucleinopathy lesions. J. Biol. Chem 2002, 277, 49071–49076.
  69. Chen, G; Bower, KA; Ma, C; Fang, S; Thiele, CJ; Luo, J. Glycogen synthase kinase 3beta (GSK3beta) mediates 6-hydroxydopamine-induced neuronal death. FASEB J 2004, 18, 1162–1164.
  70. Smith, PD; Crocker, SJ; Jackson-Lewis, V; Jordan-Sciutto, KL; Hayley, S; Mount, MP; O’Hare, MJ; Callaghan, S; Slack, RS; Przedborski, S; et al. Cyclin-dependent kinase 5 is a mediator of dopaminergic neuron loss in a mouse model of Parkinson’s disease. Proc. Natl. Acad. Sci. USA 2003, 100, 13650–13655.
  71. Avraham, E; Rott, R; Liani, E; Szargel, R; Engelender, S. Phosphorylation of Parkin by the cyclin-dependent kinase 5 at the linker region modulates its ubiquitin-ligase activity and aggregation. J. Biol. Chem 2007, 282, 12842–12850.
  72. Chung, KK; Thomas, B; Li, X; Pletnikova, O; Troncoso, JC; Marsh, L; Dawson, VL; Dawson, TM. S-nitrosylation of parkin regulates ubiquitination and compromises parkin’s protective function. Science 2004, 304, 1328–1331.
  73. Lee, G; Tanaka, M; Park, K; Lee, SS; Kim, YM; Junn, E; Lee, SH; Mouradian, MM. Casein kinase II-mediated phosphorylation regulates alpha-synuclein/synphilin-1 interaction and inclusion body formation. J. Biol. Chem 2004, 279, 6834–6839.
  74. Avraham, E; Szargel, R; Eyal, A; Rott, R; Engelender, S. Glycogen synthase kinase 3beta modulates synphilin-1 ubiquitylation and cellular inclusion formation by SIAH: Implications for proteasomal function and Lewy body formation. J. Biol. Chem 2005, 280, 42877–42886.
  75. Cookson, MR; van der Brug, M. Cell systems and the toxic mechanism(s) of alpha-synuclein. Exp. Neurol 2008, 209, 5–11.
  76. Shen, J; Cookson, MR. Mitochondria and dopamine: new insights into recessive parkinsonism. Neuron 2004, 43, 301–304.
  77. Clark, IE; Dodson, MW; Jiang, C; Cao, JH; Huh, JR; Seol, JH; Yoo, SJ; Hay, BA; Guo, M. Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. Nature 2006, 441, 1162–1166.
  78. Park, SY; Lee, SB; Lee, S; Kim, Y; Song, S; Kim, S; Bae, E; Kim, J; Shong, M; Kim, JM; et al. Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin. Nature 2006, 441, 1157–1161.
  79. Wood-Kaczmar, A; Gandhi, S; Wood, NW. Understanding the molecular causes of Parkinson’s disease. Trends Mol. Med 2006, 12, 521–528.
  80. Dodson, MW; Guo, M. Pink1, Parkin, DJ-1 and mitochondrial dysfunction in Parkinson’s disease. Curr. Opin. Neurobiol 2007, 17, 331–337.
  81. Schapira, AH. Mitochondria in the aetiology and pathogenesis of Parkinson’s disease. Lancet Neurol 2008, 7, 97–109.
  82. Pesah, Y; Pham, T; Burgess, H; Middlebrooks, B; Verstreken, P; Zhou, Y; Harding, M; Bellen, H; Mardon, G. Drosophila parkin mutants have decreased mass and cell size and increased sensitivity to oxygen radical stress. Development 2004, 131, 2183–2194.
  83. Greene, JC; Whitworth, AJ; Kuo, I; Andrews, LA; Feany, MB; Pallanck, LJ. Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants. Proc. Natl. Acad. Sci. USA 2003, 100, 4078–4083.
  84. Palacino, JJ; Sagi, D; Goldberg, MS; Krauss, S; Motz, C; Wacker, M; Klose, J; Shen, J. Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. J. Biol. Chem 2004, 279, 18614–18622.
  85. Müftüoglu, M; Elibol, B; Dalmizrak, O; Ercan, A; Kulaksiz, G; Ogüs, H; Dalkara, T; Ozer, N. Mitochondrial complex I and IV activities in leukocytes from patients with parkin mutations. Mov. Disord 2004, 19, 544–548.
  86. McBride, HM. Parkin mitochondria in the autophagosome. J. Cell Biol 2008, 183, 757–759.
  87. Poole, AC; Thomas, RE; Andrews, LA; McBride, HM; Whitworth, AJ; Pallanck, LJ. The PINK1/Parkin pathway regulates mitochondrial morphology. Proc. Natl. Acad. Sci. USA 2008, 105, 1638–1643.
  88. Park, J; Lee, G; Chung, J. The PINK1-Parkin pathway is involved in the regulation of mitochondrial remodeling process. Biochem. Biophys. Res. Commun 2009, 378, 518–523.
  89. Narendra, D; Tanaka, A; Suen, DF; Youle, RJ. Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. J. Cell Biol 2008, 183, 795–803.
  90. Gandhi, S; Muqit, MM; Stanyer, L; Healy, DG; Abou-Sleiman, PM; Hargreaves, I; Heales, S; Ganguly, M; Parsons, L; Lees, AJ; et al. PINK1 protein in normal human brain and Parkinson’s disease. Brain 2006, 129, 1720–1731.
  91. Silvestri, L; Caputo, V; Bellacchio, E; Atorino, L; Dallapiccola, B; Valente, EM; Casari, G. Mitochondrial import and enzymatic activity of PINK1 mutants associated to recessive parkinsonism. Hum. Mol. Genet 2005, 14, 3477–3492.
  92. Yang, Y; Gehrke, S; Imai, Y; Huang, Z; Ouyang, Y; Wang, JW; Yang, L; Beal, MF; Vogel, H; Lu, B. Mitochondrial pathology and muscle and dopaminergic neuron degeneration caused by inactivation of Drosophila Pink1 is rescued by Parkin. Proc. Natl. Acad. Sci. USA 2006, 103, 10793–10798.
  93. Hoepken, HH; Gispert, S; Morales, B; Wingerter, O; Del Turco, D; Mülsch, A; Nussbaum, RL; Müller, K; Dröse, S; Brandt, U; et al. Mitochondrial dysfunction, peroxidation damage and changes in glutathione metabolism in PARK6. Neurobiol. Dis 2007, 25, 401–411.
  94. van de Warrenburg, BP; Lammens, M; Lücking, CB; Denèfle, P; Wesseling, P; Booij, J; Praamstra, P; Quinn, N; Brice, A; Horstink, MW. Clinical and pathologic abnormalities in a family with parkinsonism and parkin gene mutations. Neurology 2001, 56, 555–557.
  95. Wiedemann, FR; Winkler, K; Lins, H; Wallesch, CW; Kunz, WS. Detection of respiratory chain defects in cultivated skin fibroblasts and skeletal muscle of patients with Parkinson’s disease. Ann. N. Y. Acad. Sci 1999, 893, 426–429.
  96. Kim, Y; Park, J; Kim, S; Song, S; Kwon, SK; Lee, SH; Kitada, T; Kim, JM; Chung, J. PINK1 controls mitochondrial localization of Parkin through direct phosphorylation. Biochem. Biophys. Res. Commun 2008, 377, 975–980.
  97. Plun-Favreau, H; Klupsch, K; Moisoi, N; Gandhi, S; Kjaer, S; Frith, D; Harvey, K; Deas, E; Harvey, RJ; McDonald, N; et al. The mitochondrial protease HtrA2 is regulated by Parkinson’s disease-associated kinase PINK1. Nat. Cell. Biol 2007, 9, 1243–1252.
  98. Suzuki, Y; Imai, Y; Nakayama, H; Takahashi, K; Takio, K; Takahashi, R. A serine protease, HtrA2, is released from the mitochondria and interacts with XIAP, inducing cell death. Mol. Cell 2001, 8, 613–621.
  99. Hegde, R; Srinivasula, SM; Zhang, Z; Wassell, R; Mukattash, R; Cilenti, L; DuBois, G; Lazebnik, Y; Zervos, AS; Fernandes-Alnemri, T; et al. Identification of Omi/HtrA2 as a mitochondrial apoptotic serine protease that disrupts inhibitor of apoptosis protein-caspase interaction. J. Biol. Chem 2002, 277, 432–438.
  100. Suzuki, Y; Takahashi-Niki, K; Akagi, T; Hashikawa, T; Takahashi, R. Mitochondrial protease Omi/HtrA2 enhances caspase activation through multiple pathways. Cell Death Differ 2004, 11, 208–216.
  101. Whitworth, AJ; Lee, JR; Ho, VM; Flick, R; Chowdhury, R; McQuibban, GA. Rhomboid-7 and HtrA2/Omi act in a common pathway with the Parkinson’s disease factors Pink1 and Parkin. Dis. Model Mech 2008, 1, 168–174.
  102. Strauss, KM; Martins, LM; Plun-Favreau, H; Marx, FP; Kautzmann, S; Berg, D; Gasser, T; Wszolek, Z; Müller, T; Bornemann, A; et al. Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson’s disease. Hum. Mol. Genet 2005, 14, 2099–2111.
  103. Webb, JL; Ravikumar, B; Atkins, J; Skepper, JN; Rubinsztein, DC. Alpha-Synuclein is degraded by both autophagy and the proteasome. J. Biol. Chem 2003, 278, 25009–25013.
  104. Lowe, J; Mayer, RJ; Landon, M. Ubiquitin in neurodegenerative diseases. Brain Pathol 1993, 3, 55–65.
  105. Sigismund, S; Polo, S; Di Fiore, PP. Signaling through monoubiquitination. Curr. Top. Microbiol. Immunol 2004, 286, 149–185.
  106. McNaught, KS; Jenner, P. Proteasomal function is impaired in substantia nigra in Parkinson’s disease. Neurosci. Lett 2001, 297, 191–194.
  107. Leroy, E; Boyer, R; Auburger, G; Leube, B; Ulm, G; Mezey, E; Harta, G; Brownstein, MJ; Jonnalagada, S; Chernova, T; et al. The ubiquitin pathway in Parkinson’s disease. Nature 1998, 395, 451–452.
  108. Shimura, H; Schlossmacher, MG; Hattori, N; Frosch, MP; Trockenbacher, A; Schneider, R; Mizuno, Y; Kosik, KS; Selkoe, DJ. Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson’s disease. Science 2001, 293, 263–269.
  109. Liu, Y; Fallon, L; Lashuel, HA; Liu, Z; Lansbury, PT, Jr. The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson’s disease susceptibility. Cell 2002, 111, 209–218.
  110. Kyratzi, E; Pavlaki, M; Stefanis, L. The S18Y polymorphic variant of UCH-L1 confers an antioxidant function to neuronal cells. Hum. Mol. Genet 2008, 17, 2160–2171.
  111. Maraganore, DM; Lesnick, TG; Elbaz, A; Chartier-Harlin, MC; Gasser, T; Krüger, R; Hattori, N; Mellick, GD; Quattrone, A; Satoh, J; et al. UCHL1 is a Parkinson’s disease susceptibility gene. Ann. Neurol 2004, 55, 512–521.
  112. Carmine Belin, A; Westerlund, M; Bergman, O; Nissbrandt, H; Lind, C; Sydow, O; Galter, D. S18Y in ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) associated with decreased risk of Parkinson’s disease in Sweden. Parkinsonism Relat. Disord 2007, 13, 295–298.
  113. Setsuie, R; Wada, K. The functions of UCH-L1 and its relation to neurodegenerative diseases. Neurochem. Int 2007, 51, 105–111.
  114. Wheeler, TC; Chin, LS; Li, Y; Roudabush, FL; Li, L. Regulation of synaptophysin degradation by mammalian homologues of seven in absentia. J. Biol. Chem 2002, 277, 10273–10282.
  115. Nagano, Y; Yamashita, H; Takahashi, T; Kishida, S; Nakamura, T; Iseki, E; Hattori, N; Mizuno, Y; Kikuchi, A; Matsumoto, M. Siah-1 facilitates ubiquitination and degradation of synphilin-1. J. Biol. Chem 2003, 278, 51504–51514.
  116. Engelender, S; Kaminsky, Z; Guo, X; Sharp, AH; Amaravi, RK; Kleiderlein, JJ; Margolis, RL; Troncoso, JC; Lanahan, AA; Worley, PF; et al. Synphilin-1 associates with alpha-synuclein and promotes the formation of cytosolic inclusions. Nat. Genet 1999, 22, 110–114.
  117. Chung, KK; Zhang, Y; Lim, KL; Tanaka, Y; Huang, H; Gao, J; Ross, CA; Dawson, VL; Dawson, TM. Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease. Nat. Med 2001, 7, 1144–1150.
  118. Marx, FP; Soehn, AS; Berg, D; Melle, C; Schiesling, C; Lang, M; Kautzmann, S; Strauss, KM; Franck, T; Engelender, S; et al. The proteasomal subunit S6 ATPase is a novel synphilin-1 interacting protein--implications for Parkinson’s disease. FASEB J 2007, 21, 1759–1767.
  119. Lim, KL; Chew, KC; Tan, JM; Wang, C; Chung, KK; Zhang, Y; Tanaka, Y; Smith, W; Engelender, S; Ross, CA; et al. Parkin mediates nonclassical, proteasomal-independent ubiquitination of synphilin-1: implications for Lewy body formation. J. Neurosci 2005, 25, 2002–2009.
  120. Cuervo, AM. Autophagy: many paths to the same end. Mol. Cell Biochem 2004, 263, 55–72.
  121. Dice, JF. Chaperone-mediated autophagy. Autophagy 2007, 3, 295–299.
  122. Hideshima, T; Bradner, JE; Wong, J; Chauhan, D; Richardson, P; Schreiber, SL; Anderson, KC. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc. Natl. Acad. Sci. USA 2005, 102, 8567–8572.
  123. Qiao, L; Hamamichi, S; Caldwell, KA; Caldwell, GA; Yacoubian, TA; Wilson, S; Xie, ZL; Speake, LD; Parks, R; Crabtree, D; Liang, Q. Lysosomal enzyme cathepsin D protects against alpha-synuclein aggregation and toxicity. Mol. Brain 2008, 1, 17.
  124. Rogaev, EI; Sherrington, R; Wu, C; Levesque, G; Liang, Y; Rogaeva, EA; Ikeda, M; Holman, K; Lin, C; Lukiw, WJ; et al. Analysis of the 5’ sequence, genomic structure, and alternative splicing of the presenilin-1 gene (PSEN1) associated with early onset alzheimer disease. Genomics 1997, 40, 415–424.
  125. Scheper, W; Zwart, R; Baas, F. Alternative splicing in the N-terminus of Alzheimer’s presenilin 1. Neurogenetics 2004, 5, 223–227.
  126. Smith, MJ; Sharples, RA; Evin, G; Malean, CA; Dean, B; Pavel, G; Fantino, E; Cotton, RG; Imaizumi, K; Masters, CL; et al. Expression of truncated presenilin 2 splice variant in Alzheimer’s disease, bipolar disorder, and schizophrenia brain cortex. Brain Res. Mol. Brain Res 2004, 127, 128–135.
  127. Ferrer, I; Gomez-Isla, T; Puig, B; Freixes, M; Ribé, E; Dalfó, E; Ávila, J. Current advances on different kinases involved in tau phosphorylation, and implications in Alzheimer’s disease and tauopathies. Curr. Alzheimer Res 2005, 2, 3–18.
  128. Luo, MH; Leski, ML; Andreadis, A. Tau isoforms which contain the domain encoded by exon 6 and their role in neurite elongation. J. Cell Biochem 2004, 91, 880–895.
  129. Luo, MH; Tse, SW; Memmott, J; Andreadis, A. Novel isoforms of tau that lack the microtubule-binding domain. J. Neurochem 2004, 90, 340–351.
  130. Gao, QS; Memmott, J; Lafyatis, R; Stamm, S; Screaton, G; Andreadis, A. Complex regulation of tau exon 10, whose missplicing causes frontotemporal dementia. J. Neurochem 2000, 74, 490–500.
  131. Humbert, J; Beyer, K; Carrato, C; Mate, JL; Ferrer, I; Ariza, A. Parkin and synphilin-1 isoform expression changes in Lewy body diseases. Neurobiol. Dis 2007, 26, 681–687.
  132. Beyer, K; Domingo-Sábat, M; Lao, JI; Carrato, C; Ferrer, I; Ariza, A. Identification and characterization of a new alpha-synuclein isoform and its role in Lewy body diseases. Neurogenetics 2008, 9, 15–23.
  133. Campion, D; Martin, C; Heilig, R; Charbonnier, F; Moreau, V; Flaman, JM; Petit, JL; Hannequin, D; Brice, A; Frebourg, T. The NACP/synuclein gene: chromosomal assignment and screening for alterations in Alzheimer disease. Genomics 1995, 26, 254–257.
  134. Ueda, K; Saitoh, T; Mori, H. Tissue-dependent alternative splicing of mRNA for NACP, the precursor of non-A beta component of Alzheimer’s disease amyloid. Biochem. Biophys. Res. Commun 1994, 205, 1366–1372.
  135. Beyer, K; Humbert, J; Ferrer, A; Lao, JI; Carrato, C; López, D; Ferrer, I; Ariza, A. Low alpha-synuclein 126 mRNA levels in dementia with Lewy bodies and Alzheimer disease. NeuroReport 2006, 17, 1327–1330.
  136. Beyer, K; Domingo-Sábat, M; Humbert, J; Carrato, C; Ferrer, I; Ariza, A. Differential expression of alpha-synuclein, parkin, and synphilin-1 isoforms in Lewy body disease. Neurogenetics 2008, 9, 163–172.
  137. Lee, HJ; Choi, C; Lee, SJ. Membrane-bound alpha-synuclein has a high aggregation propensity and the ability to seed the aggregation of the cytosolic form. J. Biol. Chem 2002, 277, 671–678.
  138. Beyer, K; Humbert, J; Ferrer, A; Lao, JI; Lattorre, P; López, D; Tolosa, E; Ferrer, I; Ariza, A. A variable poly-T sequence modulates alpha-synuclein isoform expression and is associated with aging. J. Neurosci. Res 2007, 85, 1538–1546.
  139. Beyer, K; Lao, JI; Carrato, C; Mate, JL; López, D; Ferrer, I; Ariza, A. Differential expression of alpha-synuclein isoforms in dementia with Lewy bodies. Neuropathol. Appl. Neurobiol 2004, 30, 601–607.
  140. Jao, CC; Der-Sarkissian, A; Chen, J; Langen, R. Structure of membrane-bound alpha-synuclein studied by site-directed spin labeling. Proc. Natl. Acad. Sci. USA 2004, 101, 8331–8336.
  141. Giasson, BI; Murray, IV; Trojanowski, JQ; Lee, VM. A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly. J. Biol. Chem 2001, 276, 2380–2386.
  142. Neystat, M; Rzhetskaya, M; Kholodilov, N; Burke, RE. Analysis of synphilin-1 and synuclein interactions by yeast two-hybrid beta-galactosidase liquid assay. Neurosci. Lett 2002, 325, 119–123.
  143. Eyal, A; Engelender, S. Synphilin isoforms and the search for a cellular model of Lewy body formation in Parkinson’s disease. Cell Cycle 2006, 5, 2082–2086.
  144. Dagata, V; Cavallaro, S. Parkin transcript variants in rat and human brain. Neurochem. Res 2004, 29, 1715–1724.
  145. Parkkinen, L; Pirttilä, T; Tervahauta, M; Alafuzoff, I. Widespread and abundant alpha-synuclein pathology in a neurologically unimpaired subject. Neuropathology 2005, 25, 304–314.
  146. Alafuzoff, I; Parkkinen, L; Al-Sarraj, S; Arzberger, T; Bell, J; Bodi, I; Bogdanovic, N; Budka, H; Ferrer, I; Gelpi, E; et al. Assessment of alpha-synuclein pathology: A study of the BrainNet Europe Consortium. J. Neuropathol. Exp. Neurol 2008, 67, 125–143.
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert